Takip et
Nir Peled
Nir Peled
Head, Shaare Zedek Cancer Center, Jerusalem, Israel
szmc.org.il üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer
M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
New England Journal of Medicine 375 (19), 1823-1833, 2016
103712016
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ...
New England journal of medicine 378 (22), 2078-2092, 2018
63352018
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
M Reck, D Rodríguez–Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
Journal of clinical oncology 37 (7), 537-546, 2019
15812019
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
14102018
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ...
Annals of Oncology 30 (8), 1321-1328, 2019
12272019
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer
S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ...
Journal of clinical oncology 38 (14), 1505-1517, 2020
10442020
Volatile organic compounds of lung cancer and possible biochemical pathways
M Hakim, YY Broza, O Barash, N Peled, M Phillips, A Amann, H Haick
Chemical reviews 112 (11), 5949-5966, 2012
9422012
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%
M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
Journal of Clinical Oncology 39 (21), 2339-2349, 2021
8462021
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ...
New England Journal of Medicine 383 (9), 813-824, 2020
8012020
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ...
Journal of thoracic oncology 13 (9), 1248-1268, 2018
6522018
Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules
MK Nakhleh, H Amal, R Jeries, YY Broza, M Aboud, A Gharra, H Ivgi, ...
ACS nano 11 (1), 112-125, 2017
5302017
Biomarkers in lung cancer screening: achievements, promises, and challenges
LM Seijo, N Peled, D Ajona, M Boeri, JK Field, G Sozzi, R Pio, JJ Zulueta, ...
Journal of Thoracic Oncology 14 (3), 343-357, 2019
4942019
Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ...
Journal of Thoracic Oncology 16 (10), 1647-1662, 2021
4722021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ...
Annals of Oncology 32 (7), 881-895, 2021
4482021
Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations
AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ...
Journal of Thoracic Oncology 11 (9), 1493-1502, 2016
4172016
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open …
JR Brahmer, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
The Lancet Oncology 18 (12), 1600-1609, 2017
3862017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ...
Journal of Clinical Oncology 35 (13), 1403-1410, 2017
3792017
Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment
N Peled, EG Abinader, G Pillar, D Sharif, P Lavie
Journal of the American College of Cardiology 34 (6), 1744-1749, 1999
3481999
Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
MC Garassino, S Gadgeel, G Speranza, E Felip, E Esteban, M Dómine, ...
Journal of Clinical Oncology 41 (11), 1992-1998, 2023
3292023
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors
E Izumchenko, K Paz, D Ciznadija, I Sloma, A Katz, D Vasquez-Dunddel, ...
Annals of Oncology 28 (10), 2595-2605, 2017
3222017
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20